MXPA03001160A - Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. - Google Patents

Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.

Info

Publication number
MXPA03001160A
MXPA03001160A MXPA03001160A MXPA03001160A MXPA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A MX PA03001160 A MXPA03001160 A MX PA03001160A
Authority
MX
Mexico
Prior art keywords
retina
optic nerve
neurodegenerative disorders
nerve head
treating neurodegenerative
Prior art date
Application number
MXPA03001160A
Other languages
English (en)
Inventor
Gustav Graff
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of MXPA03001160A publication Critical patent/MXPA03001160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el uso de acidos 3-benzoilfenilaceticos y derivados, incluyendo nepafenaco, para tratar desordenes de retina neurodegenerativos.
MXPA03001160A 2000-08-14 2001-08-13 Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. MXPA03001160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14
PCT/US2001/025319 WO2002013805A2 (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Publications (1)

Publication Number Publication Date
MXPA03001160A true MXPA03001160A (es) 2004-08-02

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001160A MXPA03001160A (es) 2000-08-14 2001-08-13 Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.

Country Status (17)

Country Link
US (1) US6638976B2 (es)
EP (1) EP1309322B1 (es)
JP (1) JP2004506010A (es)
AR (1) AR030346A1 (es)
AT (1) ATE330596T1 (es)
AU (1) AU8125801A (es)
BR (1) BR0113201A (es)
CA (1) CA2418059C (es)
CY (1) CY1106155T1 (es)
DE (1) DE60120990T2 (es)
DK (1) DK1309322T3 (es)
ES (1) ES2266229T3 (es)
HK (1) HK1057332A1 (es)
MX (1) MXPA03001160A (es)
PT (1) PT1309322E (es)
TW (1) TWI286933B (es)
WO (1) WO2002013805A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
EP1633339A4 (en) * 2003-06-13 2009-06-03 Alcon Inc FORMULATIONS OF NON-TEROIDAL ANTI-RHEUMATICS FOR THE TREATMENT OF PATHOLOGICAL OCCULAR ANGIOGENESIS
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1906916B1 (en) * 2005-05-10 2008-10-29 Alcon Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (es) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU772705B2 (en) 1999-01-07 2004-05-06 Vanderbilt University Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
CA2418059A1 (en) 2002-02-21
EP1309322A2 (en) 2003-05-14
JP2004506010A (ja) 2004-02-26
PT1309322E (pt) 2006-11-30
ATE330596T1 (de) 2006-07-15
EP1309322B1 (en) 2006-06-21
DE60120990D1 (de) 2006-08-03
BR0113201A (pt) 2006-05-09
HK1057332A1 (en) 2004-04-02
DK1309322T3 (da) 2006-10-23
DE60120990T2 (de) 2007-03-15
ES2266229T3 (es) 2007-03-01
TWI286933B (en) 2007-09-21
WO2002013805A2 (en) 2002-02-21
AU8125801A (en) 2002-02-25
US6638976B2 (en) 2003-10-28
AR030346A1 (es) 2003-08-20
CY1106155T1 (el) 2011-06-08
CA2418059C (en) 2009-12-22
US20020049255A1 (en) 2002-04-25
WO2002013805A3 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
Wassermann et al. Use and safety of a new repetitive transcranial magnetic stimulator
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
AU2436397A (en) Method of treating movement disorders by brain stimulation and drug infusion
WO2004028624A3 (en) Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
WO2002062385A3 (en) Method to prevent vision loss
CA2149924A1 (en) Use of phenserine to treat cognitive disorders
WO2000033814A3 (en) Method for administering agents to the central nervous system
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
EA200300560A1 (ru) Улучшенный способ лечения
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
MXPA03001057A (es) Metodo para tratar desordenes relacionados con la angiogenesis.
PL344574A1 (en) Cabergoline and pramipexole: new uses and combinations
WO2002078681A3 (en) Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
EP1037622A4 (en) TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS
HK1016068A1 (en) Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina of the optic nerve
WO2001043731A3 (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
WO2022092907A3 (ko) 다부위에 적용가능한 플라즈마 치료기
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
AU1521501A (en) Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Legal Events

Date Code Title Description
FG Grant or registration